Phase 2 N=12 Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP)
Pityriasis Rubra Pilaris
Primary: Clinical Improvement in PRP Severity and Body Surface Area — 15.2 units on a scale — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=14 Guselkumab in the Treatment of Pityriasis Rubra Pilaris (PRP)
Pityriasis Rubra Pilaris
Primary: Mean Change From Baseline Psoriasis Area and Severity Index (PASI) at Week-24 After Treatment With Guselkumab. — 61.8 percent change from baseline PASI
Phase 3 N=15 A Placebo-Controlled Double-Blind Study on the Safety and Efficacy of Etanercept in Palmoplantar Pustulosis
Palmoplantaris Pustulosis
Primary: Percentage Change in Palmoplantar Pustulosis Severity Index (PPPASI) Before Crossover — 30.1; 7.1 Percentage change
Phase 2 N=35 A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)
Palmoplantar Pustulosis
Primary: Log Transformed Ratio of Postbaseline Fresh Pustule Count at Day 28 to Baseline — 0.86; 0.53 Log transformed ratio — p=0.24
N/A N=23 Treatment of Keratosis Pilaris With 810 nm Diode Laser
Keratosis Pilaris (KP)
Primary: Difference in Disease Severity Scores — 4; 3 units on a scale
Phase 2 N=21 Apremilast in Patients With Moderate to Severe Palmoplantar Pustulosis (PPP) (APLANTUS)
Palmoplantar Pustulosis
Primary: Palmoplantar Pustulosis Psoriasis Area and Severity Index (PPPASI) at Week 20 Compared With Baseline — 16.50; 15.85; 16.50; 7.65 PPPASI Score — p=< 0.0001
Phase 3 N=23 Study to Evaluate the Efficacy of Infliximab Induction Therapy for Patients With Palmoplantar Psoriasis (PPP)(Study P04555)(COMPLETED)
Psoriasis
Primary: Number of Participants Who Achieve at Least 75% Improvement in Palmoplantar Psoriasis Activity Severity Index (PPPASI) After 3 Infusions. — 4 participants
Phase 3 N=176 Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP)
Palmoplantar Pustulosis
Primary: Percentage of Participants Who Achieved at Least a 50% Reduction From Baseline in Palmoplantar Pustulosis Area and Severity Index (PPPASI) Total Score (PPPASI-50) at…
N/A N=10 Dermatosis Papulosa Nigra
Facial Dermatoses · Seborrheic Keratoses
Primary: Percent Clearance of All Lesions — 88; 96; 92.5; 0 percentage of lesion clearance
Phase 2 N=24 Effects of PRK 124 Lotion in Acne Rosacea
Acne Rosacea
Primary: Erythema Severity — 44.53 Erythema percent improvement
Phase 1 N=15 Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC)
Pachyonychia Congenita
Primary: Evaluation of Systemic Absorption Through Measurement of Serum Sirolimus Trough Levels — 15; 15; 15; 14 participants
Phase 2 N=12 Topical Ruxolitinib Lichen Planus
Lichen Planus
Primary: Change in Modified Clinical Assessment Scale of Severity for Index Lesion Signs and Symptoms (mCAILS) — 11.0 score on a scale
Phase 3 N=442 Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
Chronic Plaque Psoriasis
Primary: Number of Participants Achieving Success on the Investigator Global Assessment (IGA) Scale — 99; 9 Participants — p=<0.0001
Phase 3 N=652 Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)
Atopic Dermatitis Eczema
Primary: Achievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success at Week 4 — 25.4; 10.7 percentage of participants — p=<0.0001
Phase 2 N=92 A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis
Psoriasis Vulgaris · Plaque Psoriasis
Primary: Percentage of Participants Achieving Psoriasis Area and Severity Index ≥75% (PASI 75) Improvement — 4; 1; 0 Participants
Phase 2 N=33 Efficacy of Alitretinoin Treatment in Patients With Pustular Form of Psoriasis
Psoriasis
Primary: Change From Baseline in the Palmo-plantar Pustulosis Psoriasis Area and Severity Index (PPPASI) Score at the End of Treatment (EOT) (Week 24) or at the Last Assessment…
Phase 4 N=100 Apremilast in Palmo-Plantar Psoriasis
Palmo-plantar Psoriasis
Primary: Palmoplantar Psoriasis Physician Global Assessment (PPPGA) of 0 or 1 — 7; 2 Participants
Phase 2 N=58 A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases
Chronic Idiopathic Urticaria · Chronic Idiopathic Pruritus · Lichen Planus
Primary: Change From Baseline in Weekly Average WI-NRS at Week 8 — -4.3; -1.1; -4.3; -3.7 score on a scale — p=0.3980
Phase 3 N=457 Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)
Seborrheic Dermatitis
Primary: Achievement of Success on the Investigator Global Assessment (IGA) at Week 8 — 80; 58 percentage of participants — p=<0.0001
Phase 3 N=439 Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
Chronic Plaque Psoriasis
Primary: Number of Participants Achieving Success in Investigator Global Assessment (IGA) Scale Assessment of Disease Severity at Week 8 — 108; 8 Participants — p=<0.0001
Phase 2 N=112 A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis
Seborrheic Dermatitis
Primary: The Change of F-IGA From Baseline (BL) to wk 1 Will be the Primary Efficacy Variable. — -0.9; -0.6 units on a scale — p=.009
Phase 2 N=59 Initial Dosing of BI 655130 in Palmoplantar Pustulosis Patients
Psoriasis
Primary: Percentage of Participants With Palmoplantar (pp) Pustular Psoriasis Area and Severity Index 50 (PASI) (ppPASI50) at Week 16 — 31.6; 31.6; 23.8 Percentage of…
Phase 4 N=22 Use of Platelet-rich Plasma (PRP) Therapy in Patients With Brittle Nail Syndrome
Nail Diseases
Primary: Physician Global Improvement Assessment (PGIA) — 5; 2; 7; 1 Fingernails
Phase 2 N=90 A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar Pustulosis
Palmoplantaris Pustulosis
Primary: Percentage of Participants Who Achieve a PPPASI-50 at Week 16 — 40.9; 78.3 Percentage of Partcipants — p=0.0003
Phase 3 N=237 Palmoplantar Pustular Psoriasis Efficacy and Safety With Secukinumab
Palmoplantar Pustular Psoriasis
Primary: Percentage of Participants With ppPASI 75 Response at Week 16 (Period 1) — 17.5; 26.6; 14.1 percentage of participants — p=0.5722
Phase 3 N=160 Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)
Neurodermatitis
Primary: Percentage of Participants With Greater Than or Equal to (>=) 4 Points Improvement (Reduction) From Baseline in Worst-Itch Numeric Rating Scale (WI-NRS) Scores at Week…
Phase 2 N=152 A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis
Palmoplantar Pustulosis (PPP)
Primary: The Percentage Change in Palmoplantar Pustulosis Area and Severity Index (PPP ASI) at Week 16 From Baseline — -33.6; -44.2; -48.3; -46.2 Percentage of change in PPP ASI…
Phase 4 N=30 Photodynamic Therapy for Papulopustular Rosacea
Rosacea · Papulopustular Rosacea
Primary: Improvement of the Inflammatory Lesions (Papules, Pustules, Nodules), Erythema, and Telangiectasia of Rosacea as Assessed by the Investigator's Global Assessment (IGA)…
Phase 4 N=12 A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis
Psoriatic Nail · Psoriasis Vulgaris · Psoriasis
Primary: Mean Percent Change of mNAPSI (Modified Nail Area Psoriasis Severity Index) at Week 36 Compared to Baseline for All Nails. — 64.1 percentage of reduction in mNAPSI score…
Phase 2 N=20 Topical Aprepitant in Prurigo Patients
Pruritus
Primary: Pruritus by VAS (Visual Analogue Scale) — 19.7; 21.2 mm — p=0.58